Atrial natriuretic peptide, sodium retention, and proteinuria in nephrotic syndrome

What Was Tested

Researchers studied ANP (Atrial Natriuretic Peptide) in this randomized controlled trial publication.

Oedema formation in the nephrotic syndrome is primarily due to tubular sodium retention.

The pathogenetic role of alpha atrial natriuretic peptide (ANP), a hormonal promoter of natriuresis is unknown.

Who Took Part

The abstract describes 31 patients taking part.

PubMed indexes the participants as adults, both men and women.

In 31 patients (aged 35+/-11 years) with nephrotic syndrome and histopathological evidence of primary glomerulonephritis, the researchers investigated plasma ANP concentration and its influence on renal haemodynamics, natriuresis, and proteinuria (total protein, albumin, IgG excretion).

Patients with a compensated treated form of nephrotic syndrome due to primary glomerulonephritis were included in the study.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this ANP (Atrial Natriuretic Peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Some patients received a placebo instead of ANP (Atrial Natriuretic Peptide), giving a reference point.

Diuretic medication was discontinued at least 24 h before the investigation was started.

Ten healthy subjects (group I) served as normal controls.

What Was Measured

The subject headings attached to it are Atrial Natriuretic Factor, Blood Volume, Cyclic GMP, Hemodynamics, Natriuresis, Nephrotic Syndrome and Proteinuria.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of ANP (Atrial Natriuretic Peptide) in 31 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 14 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1996 (Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association), a journal based in England.

More context: the ANP (Atrial Natriuretic Peptide) compound page, all human trials.